In addition to S1P receptor agonist and antagonists [2], SPL inhibitors represent potential treatment options for inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. The gene discussed is SGPL1; the disease is multiple sclerosis.